Steven J Isakoff

27PUBLICATIONS
206CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsMedical devices
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Jul 02, 2026
CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

|Jan 08, 2025
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).

Laura M Spring, Lauren Scarpetti, Arielle J Medford

|Jan 02, 2025
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.

Rachel O Abelman, Bogang Wu, Haley Barnes

|Jul 26, 2024
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.

Rebecca A Dent, Sung-Bae Kim, Mafalda Oliveira

|Jun 27, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.

Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa

|May 06, 2024
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer.

Aditya Bardia, Sheng Sun, Nayana Thimmiah

Pageof 5

Frequent Collaborators

12 joint publications

Leif W Ellisen

7 joint publications

Dejan Juric

6 joint publications

Aditya Bardia

6 joint publications

Seth A Wander